Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by Gabelli Funds LLC

Gabelli Funds LLC trimmed its position in shares of Elanco Animal Health Incorporated (NYSE:ELANFree Report) by 0.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 178,000 shares of the company’s stock after selling 1,500 shares during the period. Gabelli Funds LLC’s holdings in Elanco Animal Health were worth $2,001,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ELAN. JPMorgan Chase & Co. boosted its stake in Elanco Animal Health by 15.6% during the 1st quarter. JPMorgan Chase & Co. now owns 355,004 shares of the company’s stock valued at $9,262,000 after purchasing an additional 47,881 shares during the period. American Century Companies Inc. lifted its stake in shares of Elanco Animal Health by 11.8% in the 1st quarter. American Century Companies Inc. now owns 32,218 shares of the company’s stock worth $841,000 after acquiring an additional 3,396 shares during the period. US Bancorp DE lifted its stake in shares of Elanco Animal Health by 17.5% in the 1st quarter. US Bancorp DE now owns 16,263 shares of the company’s stock worth $425,000 after acquiring an additional 2,419 shares during the period. Private Advisor Group LLC acquired a new stake in shares of Elanco Animal Health in the 1st quarter worth approximately $333,000. Finally, MetLife Investment Management LLC acquired a new stake in shares of Elanco Animal Health in the 1st quarter worth approximately $232,000. 95.29% of the stock is owned by institutional investors and hedge funds.

Elanco Animal Health Stock Up 0.7 %

ELAN stock opened at $15.98 on Friday. Elanco Animal Health Incorporated has a 12 month low of $7.88 and a 12 month high of $16.08. The firm has a market cap of $7.87 billion, a PE ratio of -6.89, a P/E/G ratio of 10.10 and a beta of 1.29. The firm has a 50 day simple moving average of $14.60 and a 200 day simple moving average of $12.32. The company has a debt-to-equity ratio of 0.96, a current ratio of 2.82 and a quick ratio of 1.48.

Elanco Animal Health (NYSE:ELANGet Free Report) last released its earnings results on Tuesday, November 7th. The company reported $0.18 EPS for the quarter, beating the consensus estimate of $0.12 by $0.06. Elanco Animal Health had a negative net margin of 26.18% and a positive return on equity of 6.99%. The business had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same period in the prior year, the business earned $0.20 earnings per share. The business’s quarterly revenue was up 3.9% on a year-over-year basis. Equities research analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ELAN. Morgan Stanley raised shares of Elanco Animal Health from an “equal weight” rating to an “overweight” rating and set a $16.00 price target for the company in a research note on Friday, December 15th. Piper Sandler upped their price target on shares of Elanco Animal Health from $11.00 to $12.00 and gave the stock a “neutral” rating in a research note on Monday, November 13th. The Goldman Sachs Group upped their price target on shares of Elanco Animal Health from $10.00 to $12.50 and gave the stock a “sell” rating in a research note on Wednesday, January 17th. Jefferies Financial Group began coverage on shares of Elanco Animal Health in a research note on Tuesday, December 19th. They issued a “buy” rating and a $17.00 price target for the company. Finally, Stifel Nicolaus raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating and upped their price target for the stock from $13.00 to $20.00 in a research note on Friday, January 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Elanco Animal Health currently has a consensus rating of “Moderate Buy” and an average target price of $15.64.

Read Our Latest Report on Elanco Animal Health

Elanco Animal Health Profile

(Free Report)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

Read More

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELANFree Report).

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.